Certara, Inc. (NASDAQ: CERT) corrects 2025 EBITDA for divested unit
Certara, Inc. (NASDAQ: CERT) has issued a clarification regarding the 2025 adjusted EBITDA of its recently divested Regulatory and Medical Writing business. The company initially misstated that the $17 million adjusted EBITDA figure excluded unallocated overhead costs, but now confirms it includes them. Additionally, …